Erschienen in:
01.12.2011
Sunitinib-induced severe hypothyroidism with cardiac compromise
verfasst von:
Fiona J. Collinson, Naveen S. Vasudev, Liz Berkin, Mohammed M. Khan, Peter J. Selby, Janet E. Brown
Erschienen in:
Medical Oncology
|
Sonderheft 1/2011
Einloggen, um Zugang zu erhalten
Abstract
Tyrosine kinase inhibitors (TKI) are an increasingly used class of anti-cancer agent. Sunitinib (sutent®, Pfizer™, New York) is standard first-line therapy for patients with metastatic renal cancer. It is associated with a number of toxicities, including thyroid dysfunction. We present a case of sunitinib-induced severe hypothyroidism resulting in cardiac compromise. The case highlights the importance of interval thyroid function monitoring for patients on drugs, such as sunitinib and other TKIs.